Skip to main content
For Healthcare Professionals

TRAJENTA®

Overview

10 YEARS OF SIMPLICITY

Over the past 10 years1,2, with a simple dosing of one tablet once daily, TRAJENTA® has continued to offer patients with type 2 diabetes mellitus all over the world with proven glucose-lowering efficacy in monotherapy or in various combination therapies, and demonstrated cardiovascular and kidney safety.3

Product overview

TRAJENTA® has continued to offer patients with type 2 diabetes mellitus with proven glucose-lowering efficacy and demonstrated cardiovascular and kidney safety with a simple dosing of one tablet once daily.3

Product key facts

product_key1

Indication

TRAJENTA® is indicated to treat patients with type 2 diabetes mellitus. TRAJENTA® is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. TRAJENTA® has not been studied in patients with a history of pancreatitis, and it is unknown if using TRAJENTA® would increase the risk of developing pancreatitis in these patients.3

product_key6

Active ingredients

Linagliptin.3

product_Key7

Legal category

Prescription only medicine.3

product_key6

Dosage form and drug content

Linagliptin 5 mg film-coated tablets.3

product_key4

Administration form

Oral administration.3

 

product_key3

Pack sizes

One box contains 2-1,000 tablets in aluminum foil package.3

Taiwan NHIA reimbursement criteria2

According to the reimbursement criteria from Taiwan NHIA, TRAJENTA® is reimbursed under following conditions:

  • When TRAJENTA® is used in type 2 diabetes mellitus patients with inadequate glycemic control despite receiving treatment with maximum tolerated dose of metformin.
  • TRAJENTA® should not be used concurrently with sodium-glucose cotransporter 2 (SGLT-2) inhibitors or any fixed-dose combination drugs containing SGLT-2 inhibitors.

Footnotes:

  • DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; NHIA, National Health Insurance Administration; RA, receptor agonist; SGLT-2, sodium-glucose cotransporter 2.

References:

  1. TRAJENTA® summary of product characteristics. Renewed March 22, 2016.

  2. TRAJENTA® highlights of prescribing information. IT5253AD2911 10007261/01 IT5437AD2911 10007237/01. Revised May 2011.

  3. Trajenta® approved package insert. Updated in May 2020.

  4. Taiwan National Health Insurance Administration. Reimbursement criteria for hormones and drugs affecting hormonal mechanism. https://www.nhi.gov.tw/DL.aspx?sitessn=292&u=LzAwMS9VcGxvYWQvMjkyL3JlbGZpbGUvMC82MTMzL2NoYXA1XzExMDA2LnBkZg%3d%3d&n=Y2hhcDVfMTEwMDYucGRm&ico%20=.pdf.Accessed 02 Aug 2021.

Related News

Reporting adverse events

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.